Krystexxa resubmission for gout on track for first quarter

Savient Pharmaceuticals says that it is on track to re-file the BLA seeking an indication in chronic and treatment-failure gout for Krystexxa (pegloticase) in the first quarter of this year. It received a complete response letter for the drug from the US FDA last July.

Savient Pharmaceuticals says that it is on track to re-file the BLA seeking an indication in chronic and treatment-failure gout for Krystexxa (pegloticase) in the first quarter of this year. It received a complete response letter for the drug from the US FDA last July.

Once submitted, the company expects to be subject to a "Class 2" resubmission review cycle, meaning that an FDA decision on the drug could be expected in six months.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Immunological

More from Therapeutic Category

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By 

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.